| PATENT ASSIGNEE'S COUNTRY | USA |
| UPDATE | 09.00 |
| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 26.09.00 |
| PATENT TITLE |
Azolo triazines and pyrimidines |
| PATENT ABSTRACT |
Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivityassociated with psychopathological disturbance andstress. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | 23.07.97 |
| PATENT REFERENCES CITED |
Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide (De Souza, Nemeroff) pp. 221-224 (1990). Comprehensive Organic Synthesis (Trost, Fleming) 3:481-520 (1991). Comprehensive Organic Synthesis (Trost, Fleming) 7:762-769 (1991). Remington's Pharmaceutical Sciences (Gennaro, ed.) 17.sup.th ed. pp. 1418-1419 (1985). Arch. Pharm. (Weinheim) 320, 487-191 (1987). Psychopharmacology (Britton, Lee, Koob) 94:306-311 (1988). Life Sciences (Britton, Koob, Rivier, Vale) 31:363-367 (1982). Bull. Soc. Chim. Belg. (Maquestiau, Taghret, Eynde) vol. 101/No. 2/1992. Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide (De Souza, Nemeroff) 221-224 (No Year). J. Med. Chem. (Senga, et al.) 25:243-249 (1982). J. Med. Chem. (Senga, et al.) 25:243-249 (1982). Synapse (Battaglia, Webster, De Souza) 1:572-581 (1987). Science (Nemeroff, et al.) 226:1342 (1984). Brian Research Reviews (Dunn, Berridge) 15:71-100 (1990). Proc. Natl. Acad. Sci. (Rivier, Spiess, Vale) 80:4851-4855 (1983). Recent Progress in Hormone Research (Vale, et al.) 39:245-271 (1983). Journal of Neuroscience (De Souza, et al.) vol. 5, No. 12, pp. 3189-3203. Perspectives on Behavioral Medicine (Koob) 2:39-52 (1985). Biol. Psychiatry (France, et al.) 23:86-88 (1988). Hormones and Behavior (Berridge, Dunn) 21:393-401 (1987). Hospital Practice (De Souza) pp. 59-71 (1988). Arch. Gen. Psychiatry (Sapolsky) 46:1047-1051 (1989). Psychopharmacology (Britton, et al.) 86:170-174 (1985). Biol. Psychiatry (Arato, et al.) 25:355-359 (1989). Regulatory Peptides (Berridge, Dunn) 16:83-93 (1986). Neuropsychopharmacology (Grigoriadis, et al.) vol. 2, No. 1, pp. 53-60 (1989). Psychopharmacology (Swerdlow, Geyer, Vale, Koob) 88:147-152 (1986). Am. J. Psychiatry (Banki, et al.) 144:873-877 (1987). Arch. Gen. Psychiatry (Nemeroff, et al.) 45:577-579 (1988). New Eng. J. Med. (Gold, et al.) vol. 314, No. 21, pp. 1329-1335 (1986). Life Sciences (Morley, et al.) 41:527-544 (1987). Physiological Reviews (Blalock) vol. 69, No. 1, pp. 1-33 (1989). Journal f. prakt. Chemie. (Joshi, Dubey) Band 321, Heft 2, pp. 341-344 (1979). Journal of Medicinal Chemistry (Springer, et al.) vol. 19, No. 2, pp. 291-296 (1976). J. Heterocyclic Chem. (O'Brien, et al.) 22:601-634 (1985). J. Med. Chem. (Senga, Novinson, Wilson) 24:610-613 (1981). Science (Vale, et al.) 213:1394-1397 (1981). Chemical Abstracts, vol. 67, No. 28, 1967, abstract # 108663r. Chemical Abstracts, vol. 74, No. 28, 1971, abstract # 22867t. Chemical Abstracts, vol. 74, No. 28, 1971, abstract # 22872r. Chemical Abstracts, vol. 68, No. 28, 1968, abstract # 114635v. |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A compound of Formula (50) ##STR43## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, selected from the group consisting of: a compound of Formula (50) wherein R.sup.3 is --N(Et)(n--Bu), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --N(n--Pr) (CH.sub.2 -cyclo-Pr), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H. a compound of Formula (50) wherein R.sup.3 is --N(n--Pr).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H; a compound of Formula (50) wherein R3 is --N(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Br, R.sup.4d is H and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; and a compound of Formula (50) wherein R.sup.3 is N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H. 2. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is selected from the group consisting of: 4-(N-ethyl-N-butylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-[1,5-a]-pyrazo lo-1,3,5-triazine; 4-(N-(n-propyl)-N-(cyclopropyl)methylamino)-2,7-dimethyl-8-(2,4-dichlorophe nyl)-[1,5-a]-pyrazolo-1,3,5-triazine; 4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-[1,5-a] -pyrazolo-1,3,5-triazine; 4-(dipropylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-[1,5-a]-pyrazolo-1,3, 5-triazine; 4-(diethylamino)-2,7-dimethyl-8-(2-bromo-4-methoxyphenyl)-[1,5-a]-pyrazolo- 1,3,5-triazine; 4-(diethylamino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl)-[1,5-a]-pyra zolo-1,3,5-triazine; 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(4-bromo-2-methylphenyl)-[1,5- a]-pyrazolo-1,3,5-triazine; 4-(diethylamino)-2,7-dimethyl-8-(2-chloro-4-methoxyphenyl)-[1,5-a]-pyrazolo -1,3,5-triazine; 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-chloro-4-methoxyphenyl)-[1, 5-a]-pyrazolo-1,3,5-triazine; 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1, 5-a]-pyrazolo-1,3,5-triazine; and 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl) -[1,5-a]-pyrazolo-1,3,5-triazine. 3. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is 4-(diethylamino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl)-[1,5-a]-pyr azolo-1,3,5-triazine. 4. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound 4-(N-ethyl-N-butylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-[1,5-a]-pyraz olo-1,3,5-triazine. 5. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is 4-(N-(n-propyl)-N-(cyclopropyl)methylamino)-2,7-dimethyl-8-(2,4-dichloroph enyl)-[1,5-a]-pyrazolo-1,3,5-triazine. 6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1. 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 2. 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 3. 9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4. 10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 5. 11. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1 ,5-a]-pyrazolo-1,3,5-triazine. 12. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl )-[1,5-a]-pyrazolo-1,3,5-triazine. 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 11. 14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 12. 15. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 11. 16. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 12. 17. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 1. 18. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 2. 19. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 3. 20. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 4. 21. A method of treating anxiety or depression in mammals, comprising administering to the mammal a therapeutically effective amount of claim 5. |
| PATENT DESCRIPTION |
FIELD OF THE INVENTION This invention relates a treatment of psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivityassociated with psychopathological disturbance andstress, by administration of certain [1,5-a]-pyrazolo-1,3,5-triazines, [1,5-a]-1,2,3-triazolo-1,3,5-triazines, [1,5-a]-pyrazolo-pyrimidines and [1,5-a]-1,2,3-triazolo-pyrimidines. BACKGROUND OF THE INVENTION Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin(POMC) -derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983); G. F. Koob, Persp. Behav. Med. 2:39 (1985); E. B. De Souza et al., J. Neurosci. 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J. E. Blalock, Physiological Reviews 69:1 (1989); J. E. Morley, Life Sci. 41:527 (1987)]. Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E. B. De Souza, Hosp. Practice 23:59 (1988)]. In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C. B. Nemeroff et al., Science 226:1342 (1984); C. M. Banki et al., Am. J. Psychiatry 144:873 (1987); R. D. France et al., Biol. Psychiatry 28:86 (1988); M. Arato et al., Biol Psychiatry 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C. B. Nemeroff et al., Arch. Gen. Psychiatry 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P. W. Gold et al., Am J. Psychiatry 141:619 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P. W. Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R. M. Sapoisky, Arch. Gen. Psychiatry 46:1047 (1989)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al., Neuropsychopharmacology 2:53 (1989)]. There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine/non-benzodiazepine anxiolytics and CRF have beendemonstrated in a variety of behavioral anxietymodels [D. R. Britton et al., Life Sci. 31:363 (1982); C. W. Berridge and A. J. Dunn Regul. Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist a-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C. W. Berridge and A. J. Dunn Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990)]. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K. T. Britton et al., Psychopharmacology 86:170 (1985); K. T. Britton et al., Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N. R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Ro15-1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K. T. Britton et al., Psychopharmacology 94:306 (1988)]. The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (.alpha.-helical CRF.sub.9-41) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G. F. Koob and K. T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E. B. De Souza and C. B. Nemeroff eds., CRC Press p221 (1990)]. Several publications describe corticotropin releasing factor antagonist compounds and their use to treat psychiatric disorders and neurological diseases. Examples of such publications include DuPont Merck PCT application US94/11050 , Pfizer WO 95/33750, Pfizer WO 95/34563, Pfizer WO 95/33727 and Pfizer EP 0778 277 A1. Insofar as is known, [1,5-a]-pyrazolo-1,3,5-triazines, [1,5-a]-1,2,3-triazolo-1,3,5-triazines, [1,5-a]-pyrazolo-pyrimidines and [1,5-a]-1,2,3-triazolo-pyrimidines, have not been previously reported as corticotropin releasing factor antagonist compounds useful in the treatment of psychiatric disorders and neurological diseases. However, there have been publications which teach some of these compounds for other uses. For instance, EP 0 269 859 (Ostuka, 1988) discloses pyrazolotriazine compounds of the formula ##STR2## where R.sup.1 is OH or alkanoyl, R.sup.2 is H, OH, or SH, and R.sup.3 is an unsaturated heterocyclic group, naphthyl or substituted phenyl, and states that the compounds have xanthine oxidase inhibitory activity and are useful for treatment of gout. EP 0 594 149 (Ostuka, 1994) discloses pyrazolotriazine and pyrazolopyrimidine compounds of the formula ##STR3## where A is CH or N, R.sup.0 and R.sup.3 are H or alkyl, and R.sup.1 and R.sup.2 are H, alkyl, alkoxyl, alkylthio, nitro, etc., and states that the compounds inhibit androgen and are useful in treatment of benign prostatic hypertrophy and prostatic carcinoma. U.S. Pat. No. 3,910,907 (ICI, 1975) discloses pyrazolotriazines of the formula: ##STR4## where R.sup.1 is CH.sub.3, C.sub.2 H.sub.5 or C.sub.6 H.sub.5, X is H, C.sub.6 H.sub.5, m--CH.sub.3 C.sub.6 H.sub.4, CN, COOEt, Cl, I or Br, Y is H, C.sub.6 H.sub.5, o--CH.sub.3 C.sub.6 H.sub.4, or p--CH.sub.3 C.sub.6 H.sub.4, and Z is OH, H, CH.sub.3, C.sub.2 H.sub.5, C.sub.6 H.sub.5, n--C.sub.3 H.sub.7, i--C.sub.3 H.sub.7, SH, SCH.sub.3, NHC.sub.4 H.sub.9, or N(C.sub.2 H.sub.5).sub.2, and states that the compounds are c-AMP phosphodiesterase inhibitors useful as bronchodilators. U.S. Pat. No. 3,995,039 discloses pyrazolotriazines of the formula: ##STR5## where R.sup.1 is H or alkyl, R.sup.2 is H or alkyl, R.sup.3 is H, alkyl, alkanoyl, carbamoyl, or lower alkylcarbamoyl, and R is pyridyl, pyrimidinyl, or pyrazinyl, and states that the compounds are useful as bronchodilators. U.S. Pat. No. 5,137,887 discloses pyrazolotriazines of the formula ##STR6## where R is lower alkoxy, and teaches that the compounds are xanthine oxidase inhibitors and are useful for treatment of gout. U.S. Pat. No. 4,892,576 discloses pyrazolotriazines of the formula ##STR7## where X is O or S, Ar is a phenyl, naphthyl, pyridyl or thienyl group, R.sub.6 -R.sub.8 are H, alkyl, etc., and R.sub.9 is H, alkyl, phenyl, etc. The patent states that the compounds are useful as herbicides and plant growth regulants. U.S. Pat. No. 5,484,760 and WO 92/10098 discloses herbicidal compositions containing, among other things, a herbicidal compound of the formula ##STR8## where A can be N, B can be CR.sub.3, R.sub.3 can be phenyl or substituted phenyl, etc., R is --N(R.sub.4)SO.sub.2 R.sub.5 or --SO.sub.2 N (R.sub.6) R.sub.7 and R.sub.1 and R.sub.2 can be taken together to form ##STR9## where X, Y and Z are H, alkyl, acyl, etc. and D is O or S. U.S. Pat. No. 3,910,907 and Senga et al., J. Med. Chem., 1982, 25, 243-249, disclose triazolotriazines cAMP phosphodiesterase inhibitors of the formula ##STR10## where Z is H, OH, CH.sub.3, C.sub.2 H.sub.5, C.sub.6 H.sub.5, n--C.sub.3 H.sub.7, iso--C.sub.3 H.sub.7, SH, SCH.sub.3, NH(n--C.sub.4 H.sub.9), or N (C.sub.2 H.sub.5).sub.2, R is H or CH.sub.3, and R.sub.1 is CH.sub.3 or C.sub.2 H.sub.5. The reference lists eight therapeutic areas where inhibitors of CAMP phosphodiesterase could have utility: asthma, diabetes mellitus, female fertility control, male infertility, psoriasis, thrombosis, anxiety, and hypertension. WO95/35298 (Otsuka, 1995) discloses pyrazolopyrimidines and states that they are useful as analgesics. The compounds are represented by the formula ##STR11## where Q is carbonyl or sulfonyl, n is 0 or 1, A is a single bond, alkylene or alkenylene, R.sup.1 is H, alkyl, etc., R.sup.2 is naphthyl, cycloalkyl, heteroaryl, substituted phenyl or phenoxy, R.sup.3 is H, alkyl or phenyl, R.sup.4 is H, alkyl, alkoxycarbonyl, phenylalkyl, optionally phenylthio-substituted phenyl, or halogen, R.sup.5 and R.sup.6 are H or alkyl. EP 0 591 528 (Otsuka,1991) discloses anti-inflammatory use of pyrazolopyrimidines represented bythe formula ##STR12## where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are H, carboxyl, alkoxycarbonyl, optionally substituted alkyl, cycloalkyl, or phenyl, R.sub.5 is SR.sub.6 or NR.sub.7 R.sub.8, R.sub.6 is pyridyl or optionally substituted phenyl, and R.sub.7 and R.sub.8 are H or optionally substituted phenyl. Springer et al, J. Med. Chem., 1976, vol. 19, no. 2, 291-296 and Springer U.S. Pat. Nos. 4021,556 and 3,920,652 disclose pyrazolopyrimidines of the formula ##STR13## where R can be phenyl, substituted phenyl or pyridyl, and their use to treat gout, based on their ability to inhibit xanthine oxidase. Joshi et al., J. Prakt. Chemie, 321, 2, 1979, 341-344, discloses compounds of the formula ##STR14## where R.sup.1 is CF.sub.3, C.sub.2 F.sub.5, or C.sub.6 H.sub.4 F, and R.sup.2 is CH.sub.3, C.sub.2 H.sub.5, CF.sub.3, or C.sub.6 H.sub.4 F. Maquestiau et al., Bull. Soc. Belg., vol.101, no. 2, 1992, pages 131-136 discloses a pyrazolo[1,5-a]pyrimidine of the formula ##STR15## Ibrahim et al., Arch. Pharm. (weinheim) 320, 487-491 (1987) discloses pyrazolo[1,5-a]pyrimidines of the formula ##STR16## where R is NH2 or OH and Ar is 4-phenyl-3-cyano-2-aminopyrid-2-yl. Other references which disclose azolopyrimidines inclued EP 0 511 528 (Otsuka, 1992), U.S. Pat. No. 4,997,940 (Dow, 1991), EP 0 374 448 (Nissan, 1990), U.S. Pat. No. 4,621,556 (ICN, 1997), EP 0 531 901 (Fujisawa, 1993), U.S. Pat. No. 4,567,263 (BASF, 1986), EP 0 662 477 (Isagro, 1995), DE 4 243 279 (Bayer, 1994), U.S. Pat. No. 5,397,774 (Upjohn, 1995), EP 0 521 622 (Upjohn, 1993), WO 94/109017 (Upjohn, 1994), J. Med. Chem., 24, 610-613 (1981), and J. Het. Chem., 22, 601 (1985). |
| PATENT EXAMPLES | This data is not available for free |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |